https://www.selleckchem.com/products/cb-5083.html
Over the past few decades, strains increased their pathogenicity and antibiotic resistance, thereby becoming a major therapeutic challenge. One of the few available therapeutic options seems to be intravenous fosfomycin. Unfortunately, the determination of sensitivity to fosfomycin performed in hospital laboratories can pose a significant problem. Therefore, the aim of the present research was to evaluate the activity of fosfomycin against clinical, multidrug-resistant strains isolated from nosocomial infections between 2011 and 2020, a
Like
Comment
Share
